Glycomimetics INC Form 4 insider transactions

A group of investment funds led by BVF Partners L.P. has reported a substantial increase in their beneficial ownership of GlycoMimetics Inc. common stock and pre-funded warrants following the completion of a reverse merger with Crescent Biopharma, Inc.

GlycoMimetics, Inc. provides supplemental disclosures regarding its previously announced reverse merger with Crescent Biopharma, Inc., detailing the strategic rationale, valuation terms, and a significant concurrent PIPE financing.

GlycoMimetics, Inc. announced that its acquisition target, Crescent Biopharma, Inc., will present at the Jefferies Global Healthcare Conference as the companies anticipate closing their merger in Q2 2025.

GlycoMimetics, Inc. amends its merger agreement with Crescent Biopharma, Inc. to clarify the treatment of restricted stock units and voting mechanics, with GlycoMimetics securityholders expected to own approximately 2.6% of the combined company post-merger.

Crescent Biopharma appoints David Lubner, a seasoned finance executive, to its board of directors as the company prepares for its acquisition by GlycoMimetics.

Crescent Biopharma announces key leadership appointments, including Joshua Brumm as CEO, to advance its pipeline of oncology therapeutics, with an IND submission for its lead program expected in Q4 2025.

GlycoMimetics, Inc. and Crescent Biopharma, Inc. are set to merge, focusing on advancing Crescent's oncology programs, particularly its novel PD-1 x VEGF bispecific antibody, CR-001.

GlycoMimetics, Inc. is set to acquire Crescent Biopharma, Inc. through a merger agreement, aiming to advance cancer therapy innovation.

Crescent Biopharma announces key executive appointments as it progresses towards a reverse merger with GlycoMimetics and advances its oncology pipeline.

GlycoMimetics reports the termination of its Apollomics collaboration agreement, resignations of multiple board members, and the departure of its CEO and CFO.

GlycoMimetics and Crescent Biopharma amend their merger agreement, altering the financing structure and SEC filing process while maintaining the expected exchange ratio and ownership percentages.

Invus Public Equities, L.P. reports the sale of GlycoMimetics Inc. common stock in two transactions on August 7 and 8, 2024.

Invus Public Equities, L.P. reports selling shares of GlycoMimetics Inc. at weighted average prices of $0.1884 and $0.1828, reducing its holdings.

Invus Public Equities, L.P., a 10% owner of GlycoMimetics Inc, reports selling shares of common stock in two transactions on August 1st and 2nd, 2024.

Invus Public Equities, L.P. reports the sale of GlycoMimetics Inc. shares across multiple transactions between July 26 and July 30, 2024.

Edwin Rock, Chief Medical Officer of GlycoMimetics, recently purchased a significant number of shares in the company, signaling confidence in its future.

Brian M. Hahn, SVP Finance and CFO of GlycoMimetics, Inc., recently purchased 17,500 shares of the company's common stock on the open market.

A Form 4 filing reveals that GlycoMimetics director Scott Koenig acquired 40,000 stock options on May 1, 2024.

Mark Alan Goldberg, a director of GlycoMimetics, Inc., acquired stock options for 40,000 shares on May 1, 2024.

Director Timothy R. Pearson of GlycoMimetics, Inc. reports acquisition of stock options.

Director Rachel K. King acquired stock options for 40,000 shares of GlycoMimetics, Inc. on May 1, 2024.

Patricia S. Andrews, a director of GlycoMimetics Inc., acquired stock options for 40,000 shares on May 1, 2024.

Director Scott Thomas Jackson acquires stock options in GlycoMimetics, Inc.

Director Daniel M. Junius acquired stock options for 40,000 shares of GlycoMimetics Inc. at an exercise price of $1.62 on May 1, 2024.

Director Daniel M. Junius acquired 5,209 shares of GlycoMimetics Inc. common stock on March 29, 2024, in lieu of board and committee retainer fees.

Director Rachel K. King acquired 3,334 shares of GlycoMimetics stock on March 29, 2024, in lieu of $10,000 in board and committee retainer fees.

Mark Alan Goldberg, a director at GlycoMimetics, acquired 4,584 shares of common stock in lieu of board and committee retainer fees.